These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10622579)

  • 1. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C.
    Thomas HC; Török ME; Forton DM; Taylor-Robinson SD
    J Hepatol; 1999; 31 Suppl 1():152-9. PubMed ID: 10622579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
    Scott LJ; Perry CM
    Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
    Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
    J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study.
    Rumi MG; Aghemo A; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
    Antivir Ther; 2007; 12(7):1033-40. PubMed ID: 18018761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients.
    Fujita N; Kaito M; Tanaka H; Horiike S; Urawa N; Sugimoto R; Konishi M; Watanabe S; Adachi Y
    J Viral Hepat; 2006 Mar; 13(3):190-8. PubMed ID: 16475995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts).
    Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
    Clin Ter; 2006; 157(5):457-68. PubMed ID: 17147054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
    Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
    Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
    Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
    Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
    Kim KI; Kim SR; Sasase N; Taniguchi M; Harada S; Kinoshita K; Kim SH; Akimoto Y; Shikata M; Kimura N; Izawa S; Ohtani A; Nakao K; Motojima M; Kinoshita M; Hirai M; Ohzu M; Hirooka T; Nabeshima S; Ishii F; Tanaka K; Hotta H
    J Clin Pharm Ther; 2006 Oct; 31(5):441-6. PubMed ID: 16958821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C.
    Pawlotsky JM
    Antiviral Res; 2003 Jun; 59(1):1-11. PubMed ID: 12834855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
    Zylberberg H; Benhamou Y; Lagneaux JL; Landau A; Chaix ML; Fontaine H; Bochet M; Poynard T; Katlama C; Pialoux G; Bréchot C; Pol S
    Gut; 2000 Nov; 47(5):694-7. PubMed ID: 11034587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy.
    Bellobuono A; Mondazzi L; Tempini S; Chiodo F; Magliano E; Furione L; Idéo G
    J Hepatol; 2000 Sep; 33(3):463-8. PubMed ID: 11020003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
    Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
    J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study.
    Bjøro K; Bell H; Hellum KB; Skaug K; Raknerud N; Sandvei P; Døskeland B; Maeland A; Lund-Tønnesen S; Myrvang B
    Scand J Gastroenterol; 2002 Feb; 37(2):226-32. PubMed ID: 11843062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
    Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S
    Digestion; 2000; 61(2):90-7. PubMed ID: 10705172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.